---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-018954"
form_type: "8-K/A"
ticker: "INDP"
cik: "0001857044"
company_name: "Indaptus Therapeutics, Inc."
filed_at: "2026-04-24T23:59:59+00:00"
generated_at: "2026-05-15T04:14:38.904442+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# Indaptus Therapeutics Appoints Tim Ruan and Johnny Fox Arrowsmith as Independent Directors; Matthew McMurdo Resigns

## Summary
- Tim Ruan, 40, CFO of Ocumension Therapeutics and former Executive Director at Goldman Sachs, appointed as Class II director.
- Dr. Johnny Fox Arrowsmith (Yi Zhang), 48, partner at JunHe and registered patent attorney, appointed as Class II director.
- Matthew McMurdo resigned as director on April 22, 2026; resignation not due to any disagreement with company.
- Each new director receives annual cash retainer of $30,000, payable quarterly, plus expense reimbursement and indemnification.
- Ruan appointed to Audit Committee; Arrowsmith appointed to Nominating Committee. New directors effective April 22, 2026.

## SEC filing metadata
- accession: 0001493152-26-018954
- form_type: 8-K/A
- ticker: INDP
- cik: 0001857044
- company_name: Indaptus Therapeutics, Inc.
- filed_at: 2026-04-24T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1857044/000149315226018954/0001493152-26-018954-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1857044/000149315226018954/form8-ka.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-018954
- JSON: https://secwatch.observer/filing/0001493152-26-018954.json
- Plain text: https://secwatch.observer/filing/0001493152-26-018954.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.